Risk Factors for Medication-Induced Diabetes and Type 2 Diabetes

Amed, Shazhan; Dean, Heather; Sellers, Elizabeth; Panagiotopoulos, Constadina; Shah, Baiju R.; Booth, Gillian L.; Laubscher, Tessa; Dannenbaum, David; Hadjiyannakis, Stasia; Hamilton, Jill

doi:10.1016/j.jpeds.2011.01.017

Cited by 21 publications

(29 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Steroid-induced hyperglycemia and diabetes have been reported in post-transplant patients, children with ALL, and those undergoing treatment for nephrotic syndrome [97,98]. There have also been reports of diabetic ketoacidosis at presentation in these children [97,98]. …”

Section: Adverse Events Associated With Long-term Systemic Corticostementioning

confidence: 99%

“…Although obesity has been described as a potential risk factor, a retrospective Canadian study of children < 18 years of age found that, compared to those with established type 2 diabetes, those with medication-induced diabetes were less likely to be obese, have a positive family history of type 2 diabetes, and have obesity-related comorbidities (e.g., dyslipidemia, hypertension or elevated alanine aminotransferase levels) [97]. Therefore, evaluating for the typical type 2 diabetes risk factors may not be sufficient for identifying children at-risk of developing steroid-induced hyperglycemia or diabetes.…”

Section: Adverse Events Associated With Long-term Systemic Corticostementioning

confidence: 99%

See 1 more Smart Citation

A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy

Liu

Ahmet

Ward

et al. 2013

All Asth Clin Immun

974

760

View full text Add to dashboard Cite

Systemic corticosteroids play an integral role in the management of many inflammatory and immunologic conditions, but these agents are also associated with serious risks. Osteoporosis, adrenal suppression, hyperglycemia, dyslipidemia, cardiovascular disease, Cushing’s syndrome, psychiatric disturbances and immunosuppression are among the more serious side effects noted with systemic corticosteroid therapy, particularly when used at high doses for prolonged periods. This comprehensive article reviews these adverse events and provides practical recommendations for their prevention and management based on both current literature and the clinical experience of the authors.

show abstract

Section: Adverse Events Associated With Long-term Systemic Corticostementioning

confidence: 99%

Section: Adverse Events Associated With Long-term Systemic Corticostementioning

confidence: 99%

A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy

Liu

Ahmet

Ward

et al. 2013

All Asth Clin Immun

974

760

View full text Add to dashboard Cite

show abstract

“…[5][6][7]12,13 However, several conflicting results in more recent studies have indicated the absence of significant associations between weight status and hyperglycemic episodes. 8,[14][15][16] Given the rising rate of obesity and overweight among Taiwanese children, in the past ten years, those who receive treatment for leukemia may be at a higher risk for secondary hyperglycemia. Because ALL treatment protocol evolves over time, the side effects of therapy should be continually reevaluated.…”

Section: A C C E P T E D Accepted Manuscriptmentioning

confidence: 99%

Risk Factors for Hyperglycemia During Chemotherapy for Acute Lymphoblastic Leukemia Among Taiwanese Children

Tsai

Huang

Chou

et al. 2015

Pediatrics & Neonatology

View full text Add to dashboard Cite

show abstract

“…Almost all children and adolescents with T2DM are also overweight or obese, and excess adiposity, particularly visceral adiposity, is associated with insulin resistance (Dabelea et al 2007;Haines et al 2007;Amed et al 2010b). Studies with US and Canadian youth have found that 75-95% of those with T2DM are obese (BMI percentile > 95th for age and sex) (Mayer- Amed et al 2010b;Liu et al 2009;Lawrence et al 2009b;Bell et al 2009).…”

Section: Childhood Overweight and Obesitymentioning

confidence: 99%

“…Studies with US and Canadian youth have found that 75-95% of those with T2DM are obese (BMI percentile > 95th for age and sex) (Mayer- Amed et al 2010b;Liu et al 2009;Lawrence et al 2009b;Bell et al 2009). Another study in obese children found that 25% of obese children 4-10 years of age and 21% of 11-18 years of age were found to have an impaired glucose tolerance.…”

Section: Childhood Overweight and Obesitymentioning

confidence: 99%

Pediatric Type 2 Diabetes: Prevention and Treatment Through a Life Course Health Development Framework

Salsberry

Tanda

Anderson

et al. 2017

Handbook of Life Course Health Development

View full text Add to dashboard Cite

Estimates project that one in three US adults may have diabetes in 2050. Until very recently, type 2 diabetes mellitus (T2DM) was a disease diagnosed in adults, but as the childhood obesity epidemic has spread, the diagnosis of T2DM in adolescents has become more common. Early indicators suggest that the disease may be more severe and more difficult to manage when diagnosed in adolescents. It is projected that adolescents with T2DM will lose approximately 15 years of life. The economic burden of T2DM rises significantly as the years with disease increase. This grim forecast highlights that not only will the disease burden be significant but the economic burden will be high. The risk for developing T2DM begins in utero. Individual health development trajectories build from this starting point, the result of multiple factors that accumulate across time and are the result of biological conditioning during sensitive developmental periods. A major aim of this chapter is to demonstrate that a life course health development approach to pediatric T2DM is critical to a sound national strategy to prevent and treat pediatric T2DM. We review major factors known to influence the development of pediatric T2DM and track these across childhood. While these factors will likely change over the next decade, what will not change is the importance of placing these factors into context and recognizing that T2DM development is highly sensitive to the timing and social structures of multiple environmental exposures. Research recommendations are discussed through a life course lens.

show abstract

Risk Factors for Medication-Induced Diabetes and Type 2 Diabetes

Cited by 21 publications

References 26 publications

A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy

A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy

Risk Factors for Hyperglycemia During Chemotherapy for Acute Lymphoblastic Leukemia Among Taiwanese Children

Pediatric Type 2 Diabetes: Prevention and Treatment Through a Life Course Health Development Framework

Contact Info

Product

Resources

About